Reuters:

Apple convinced a federal jury on Friday that early versions of health monitoring tech company Masimo’s smartwatches infringe two of its design patents as part of a broader intellectual property dispute between the companies. The jury, in Delaware, agreed with Apple that previous iterations of Masimo’s W1 and Freedom watches and chargers willfully violated Apple’s patent rights in smartwatch designs.

But the jury awarded the tech giant, which is worth about $3.5 trillion, just $250 in damages — the statutory minimum for infringement in the United States. Apple’s attorneys told the court the “ultimate purpose” of its lawsuit was not money, but to win an injunction against sales of Masimo’s smartwatches after an infringement ruling.

On that front, jury also determined that Masimo’s current watches did not infringe Apple patents covering inventions that the tech giant had accused Masimo of copying.

$250 is just enough for Apple to buy one of its own 40mm Apple Watch SE models. (No sales tax in Delaware.) That’s about all Apple got out of this. This victory doesn’t change the ITC import ban that prevents Apple from enabling the blood oxygen sensor on watches sold in the U.S. after December 2023. It might have, if Apple had been able to win a verdict holding that Masimo’s current watches also infringe patents held by Apple. Florian Mueller, writing at IP Fray:

In order to understand the reason why Apple sued over a product practically no one buys, one has to understand the indirect ramifications for Masimo’s U.S. import ban on Apple Watches with a pulse oximetry feature. Only the indirect implications matter in this case. The short version is that if Masimo couldn’t have continued to sell its own smartwatch, they’d have lost a legally required basis for preventing Apple from selling smartwatches.